Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying breast cancer patients who have a positive sentinel lymph node after receiving neoadjuvant systemic treatment. The trial evaluates whether axillary radiotherapy ART reduces the risk of lymphedema compared to axillary lymph node dissection ALND in these patients. The study also examines recurrence and overall survival rates, as well as quality of life. This is a prospective, randomized, open-label, parallel group, multicenter study involving approximately 820 patients over 5 years. Participants are divided into two groups one receives axillary radiotherapy without lymphadenectomy, including radiation to levels I and II axilla, level III, supraclavicular area, and possibly the internal mammary chain the other group undergoes axillary lymph node dissection plus radiotherapy to level III, supraclavicular area, and possibly the internal mammary chain. Patients are stratified by neoadjuvant treatment type chemotherapy or hormone therapy. A pilot phase with the first 200 patients has been completed, and interim analysis will be performed. During the study, participants undergo evaluations including imaging by ultrasound or MRI to assess axillary response after neoadjuvant therapy. Researchers will track disease-free survival up to 5 years, overall survival up to 5 years, and incidence of lymphedema up to 3 years after surgery. Quality of life and safety outcomes will also be monitored. The study aims to provide data on whether avoiding lymphadenectomy is a viable option for patients responding well to neoadjuvant treatment.
Actively Recruiting
Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.
Actively Recruiting
Researchers are comparing two care models for adults with type 2 diabetes who have poor blood sugar control. The study evaluates the impact of care led by a dietitian-nutritionist versus care provided in a day hospital setting by a nurse and an endocrinologist. The goal is to see which approach better affects glycated hemoglobin HbA1c levels after three months. Participants receive clinical follow-up either in a day hospital where care is provided jointly by a nurse and an endocrinologist, or in an ambulatory care unit where a dietitian-nutritionist and an endocrinologist manage their care. This observational study observes patients who were treated under these two different care settings before and after 2024. During the study, participants metabolic control is monitored, focusing on glycated hemoglobin measured three months after the intervention. The research team collects relevant clinical data to compare outcomes between the two care models. The total study period extends until April 2027, allowing for thorough follow-up and data analysis.
Actively Recruiting
Researchers are evaluating the safety of remote consultations, including video and telephone appointments, compared to traditional face-to-face consultations for patients in a hospital setting. This randomized controlled trial aims to assess whether remote follow-up is as safe as in-person visits by measuring complications related to the patients underlying diseases over a 12-month period. The study includes a total of 2136 patients randomly assigned to one of three groups face-to-face consultation, video consultation, or telephone consultation. Participants will receive follow-up care through either in-person visits or remote consultations delivered by phone or video. Physicians will schedule at least three visits per participant a baseline screening visit, several intermediate visits based on medical need, and a final visit around 12 months after enrollment or earlier if the patient is discharged or discontinues early. Remote consultation patients will be reminded of appointments via text or call. Telephone consultations involve the doctor calling the patient or their family at the scheduled time, while video consultations use a secure application with a virtual waiting room. During the study, participants will be monitored for complications, serious adverse events, avoidable hospitalizations, and unscheduled medical contacts. Researchers will also evaluate healthcare costs, usability of the video system, and satisfaction of both patients and health professionals with the care process. All interactions, including phone calls for control participants, will be recorded. The total participation duration is about 12 months, with physicians able to schedule or cancel appointments as needed throughout this period.
Actively Recruiting
Researchers are evaluating the use of tofacitinib in children and adolescents under 18 years old diagnosed with juvenile idiopathic arthritis JIA. The study aims to understand how effective tofacitinib is in improving disease control over a 12-month period using real-world clinical data. This observational study is led by the Consorci Sanitari de lAlt Peneds i Garraf. Participants in this study are those with JIA who have been prescribed tofacitinib as part of their treatment. The study does not assign treatment but observes patients already using tofacitinib in routine clinical practice. The main focus is on monitoring clinical outcomes over the course of one year after starting tofacitinib. During the study, researchers will review medical records and clinical data to assess disease activity using the Juvenile Arthritis Disease Activity Score JADAS-10 at the start and after 12 months of treatment. No additional interventions are administered as part of the study. Participants ongoing care continues with their usual healthcare providers, and the study monitors outcomes based on standard clinical assessments documented in regular practice.